These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27506636)

  • 1. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less.
    Toss A; Palazzo J; Berger A; Guiles F; Sendecki JA; Simone N; Anne R; Avery T; Jaslow R; Lazar M; Tsangaris T; Cristofanilli M
    Breast; 2016 Oct; 29():223-30. PubMed ID: 27506636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
    Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ductal carcinoma in situ: a disease entity that merits more recognition.
    Dereere E; Papadimitriou K; Tjalma W; Altintas S
    Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationships between HER2 Overexpression and DCIS Characteristics.
    Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
    Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
    Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
    Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
    J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
    Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
    Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
    Pilewskie M; Olcese C; Patil S; Van Zee KJ
    Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of ductal carcinoma in situ in the modern era.
    Khan A; Dumitru D; Catanuto G; Rocco N; Nava MB; Benson J
    Minerva Chir; 2018 Jun; 73(3):303-313. PubMed ID: 29589680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
    Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
    Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in the Treatment of Ductal Carcinoma in Situ.
    Barrio AV; Van Zee KJ
    Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.